Zhang Peng, Huang Yixian, Liu Hao, Marquez Rebecca T, Lu Jianqin, Zhao Wenchen, Zhang Xiaolan, Gao Xiang, Li Jiang, Venkataramanan Raman, Xu Liang, Li Song
Center for Pharmacogenetics, University of Pittsburgh, Pittsburgh, PA 15261, USA; Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, USA; University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Department of Molecular Biosciences, University of Kansas Cancer Center, University of Kansas, Lawrence, KS 66045, USA; Department of Radiation Oncology, University of Kansas Cancer Center, University of Kansas, Lawrence, KS 66045, USA.
Biomaterials. 2014 Aug;35(25):7146-56. doi: 10.1016/j.biomaterials.2014.04.108. Epub 2014 May 22.
We report here that a simple, well-defined, and easy-to-scale up nanocarrier, PEG5000-lysyl-(α-Fmoc-ε-t-Boc-lysine)2 conjugate (PEG-Fmoc), provides high loading capacity, excellent formulation stability and low systemic toxicity for paclitaxel (PTX), a first-line chemotherapeutic agent for various types of cancers. 9-Fluorenylmethoxycarbonyl (Fmoc) was incorporated into the nanocarrier as a functional building block to interact with drug molecules. PEG-Fmoc was synthesized via a three-step synthetic route, and it readily interacted with PTX to form mixed nanomicelles of small particle size (25-30 nm). The PTX loading capacity was about 36%, which stands well among the reported micellar systems. PTX entrapment in this micellar system is achieved largely via an Fmoc/PTX π-π stacking interaction, which was demonstrated by fluorescence quenching studies and (13)C NMR. PTX formulated in PEG-Fmoc micelles demonstrated sustained release kinetics, and in vivo distribution study via near infrared fluorescence imaging demonstrated an effective delivery of Cy5.5-labled PTX to tumor sites. The maximal tolerated dose for PTX/PEG-Fmoc (MTD > 120 mg PTX/kg) is higher than those for most reported PTX formulations, and in vivo therapeutic study exhibited a significantly improved antitumor activity than Taxol, a clinically used formulation of PTX. Our system may hold promise as a simple, safe, and effective delivery system for PTX with a potential for rapid translation into clinical study.
我们在此报告,一种简单、明确且易于扩大规模的纳米载体,聚乙二醇5000-赖氨酸-(α-芴甲氧羰基-ε-叔丁氧羰基-赖氨酸)2缀合物(PEG-Fmoc),对紫杉醇(PTX)具有高载药量、出色的制剂稳定性和低全身毒性,PTX是用于治疗多种癌症的一线化疗药物。9-芴甲氧羰基(Fmoc)作为功能性结构单元被引入纳米载体中,以与药物分子相互作用。PEG-Fmoc通过三步合成路线合成,它能轻易地与PTX相互作用形成小粒径(25-30nm)的混合纳米胶束。PTX的载药量约为36%,在已报道的胶束系统中表现良好。该胶束系统中PTX的包封主要通过Fmoc/PTX π-π堆积相互作用实现, 荧光猝灭研究和(13)C NMR证实了这一点。用PEG-Fmoc胶束配制的PTX表现出缓释动力学,通过近红外荧光成像进行的体内分布研究表明,Cy5.5标记的PTX能有效递送至肿瘤部位。PTX/PEG-Fmoc的最大耐受剂量(MTD>120mg PTX/kg)高于大多数已报道的PTX制剂,体内治疗研究显示其抗肿瘤活性比临床使用的PTX制剂紫杉醇有显著提高。我们的系统有望成为一种简单、安全且有效的PTX递送系统,并有可能迅速转化为临床研究。